Bristol/ImClone Erbitux BLA Resubmission Expected During First Quarter

ImClone expects to resubmit the BLA for Erbitux (cetuximab) during the first quarter after addressing the issues raised in FDA's "refuse-to-file" letter for the colorectal cancer treatment